Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022.
Saved in:
| Title: | Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022. |
|---|---|
| Authors: | DeSilva MB; HealthPartners Institute, Minneapolis, Minnesota, USA., Mitchell PK; Westat, Rockville, Maryland, USA., Klein NP; Kaiser Permanente Northern California Division of Research, Kaiser Permanente Vaccine Study Center, Oakland, California, USA., Dixon BE; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA., Tenforde MW; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Thompson MG; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Naleway AL; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA., Grannis SJ; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; School of Medicine, Indiana University, Indianapolis, Indiana, USA., Ong TC; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Natarajan K; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.; New York Presbyterian Hospital, New York, New York, USA., Reese SE; Westat, Rockville, Maryland, USA., Zerbo O; Kaiser Permanente Northern California Division of Research, Kaiser Permanente Vaccine Study Center, Oakland, California, USA., Kharbanda AB; Children's Minnesota, Minneapolis, Minnesota, USA., Patel P; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Stenehjem E; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA., Raiyani C; Baylor Scott and White Health, Temple, Texas, USA., Irving SA; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA., Fadel WF; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA., Rao S; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Han J; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA., Reynolds S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Davis JM; Westat, Rockville, Maryland, USA., Lewis N; Kaiser Permanente Northern California Division of Research, Kaiser Permanente Vaccine Study Center, Oakland, California, USA., McEvoy C; HealthPartners Institute, Minneapolis, Minnesota, USA., Dickerson M; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Dascomb K; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA., Valvi NR; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA., Barron MA; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Goddard K; Kaiser Permanente Northern California Division of Research, Kaiser Permanente Vaccine Study Center, Oakland, California, USA., Vazquez-Benitez G; HealthPartners Institute, Minneapolis, Minnesota, USA., Grisel N; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA., Mamawala M; Baylor Scott and White Health, Temple, Texas, USA., Embi PJ; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Fireman B; Kaiser Permanente Northern California Division of Research, Kaiser Permanente Vaccine Study Center, Oakland, California, USA., Essien IJ; HealthPartners Institute, Minneapolis, Minnesota, USA., Griggs EP; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Arndorfer J; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA., Gaglani M; Baylor Scott and White Health, Temple, Texas, USA.; Texas A&M University College of Medicine, Temple, Texas, USA. |
| Source: | The Journal of infectious diseases [J Infect Dis] 2023 Apr 18; Vol. 227 (8), pp. 961-969. |
| Publication Type: | Journal Article; Research Support, U.S. Gov't, P.H.S. |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6613 |
|---|---|
| DOI: | 10.1093/infdis/jiac458 |
